## PRESS RELEASE

## WOLF THEISS HAS ADVISED CELLINK AB ON A \$68 MILLION ACQUISITION OF IN-VITRO TECH CORPORATION

Bratislava, 28 July 2021 – Wolf Theiss has advised CELLINK AB, a Swedish 3D bioprinter manufacturer, on the acquisition of the in-vitro technology specialist MatTek Corporation, for a value of \$68 million.

MatTek Corporation, a Boston-area life sciences company specialising in labengineered human tissue production, has recently been acquired by CELLINK, a leader in bioprinting, multi-omics, cell line development and diagnostics.

For nearly 30 years, MatTek has been a global leader in the production of labgrown human tissue models used for testing pharmaceuticals, cosmetic and personal care products as more physiologically relevant alternatives to animal testing. With the largest portfolio of proprietary 3D human-derived tissue and disease models in the world, MatTek's tissues are used in product development and regulatory testing across North America, Europe, and Asia.

Wolf Theiss acted as one of the legal advisors to CELLINK in connection with the acquisition of all outstanding equity interests of MatTek Corporation in Slovakia. The Slovak team included Bruno Štefánik (Counsel, Bratislava), Zuzana Hodoňová (Counsel, Bratislava), Dalibor Palatický (Associate, Bratislava) and Jozef Virčík (Associate, Bratislava).

The acquisition offers market-leading alternative in-vitro methods and replaces animal testing by providing alternative test models. These solutions allow researchers to gather better data through more physiologically relevant models and therefore to make better predictions. Additionally, providing alternative testing models, enables the reduction, and in some cases the elimination, of animal testing.

As a result of the successful transaction, Cellink praised Wolf Theiss for providing excellent counsel and legal services.

CELLINK AB is the leading bioconvergence company in world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries.

WOLF THEISS Rechtsanwälte Aupark Tower, Einsteinova 24 851 01 Bratislava Slovak Republic T +421 2 5910 1240 F +421 2 5910 1249 bratislava@wolftheiss.com www.wolftheiss.com

## **ABOUT WOLF THEISS**

Wolf Theiss is one of the leading European law firms in Central, Eastern and South-Eastern Europe with a focus on international business law. With 340 lawyers in 13 countries, over 80% of the firm's work involves cross-border representation of international clients. Combining expertise in law and business, Wolf Theiss develops innovative solutions that integrate legal, financial and business know-how.

For further information please contact:

Miroslava Nehajova BDM Assistant

Wolf Theiss Rechtsanwälte / Attorneys-at-Law Aupark Tower, Einsteinova 24, 851 01 Bratislava Slovak Republic Tel.: +421 2 591 012 39 E-Mail: miroslava.nehajova@wolftheiss.com

Find out more at www.wolftheiss.com

